Machine Perfusion of Lungs

  • Toshihiro OkamotoEmail author
  • Hiromichi Niikawa
  • Kamal Ayyat
  • Ichiro Sakanoue
  • Sayf Said
  • Kenneth R. McCurryEmail author
Machine Preservation of the Liver (C Miller and C Quintini, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Machine Preservation of the Liver


Purpose of Review

The purpose of this review is to summarize the fundamentals, rationale, research topics, and clinical outcomes of ex vivo lung perfusion.

Recent Findings

Since the first clinical case in 2000, the usefulness of ex vivo lung perfusion to increase the donor lung pool has been supported by much evidence. The main role of ex vivo lung perfusion is to evaluate, preserve, and treat lungs that otherwise might not be useable for transplantation. Many studies have been conducted to evaluate the optimal perfusate, flow, method of evaluation, markers of lung performance, and possible treatment strategies. Moreover, during the last decade, clinical trials have demonstrated comparable clinical outcomes to lung transplants performed with standard donors without EVLP.


Ex vivo lung perfusion is an effective tool to evaluate lungs and to salvage rejected donor lungs to increase the donor lung pool.


Ex vivo lung perfusion Lung transplantation Lung donor 


Compliance with Ethical Standards

Conflict of Interest

Kamal Ayyat has a patent (16/269,389) pending.

Toshihiro Okamoto, Hiromichi Niikawa, Ichiro Sakanoue, Sayf Said, and Kenneth R. McCurry declare no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Valapour M, Skeans M, Smith J, Edwards L, Cherikh W, Uccellini K, et al. OPTN/SRTR 2015 annual data report: lung. Am J Transplant. 2017;17:357–424. Scholar
  2. 2.
    Cypel M, Yeung JC, Liu M, Anraku M, Chen F, Karolak W, et al. Normothermic ex vivo lung perfusion in clinical lung transplantation. N Engl J Med. 2011;364(15):1431–40. Scholar
  3. 3.
    •• Warnecke G, Van Raemdonck D, Smith MA, Massard G, Kukreja J, Rea F, et al. Normothermic ex-vivo preservation with the portable Organ Care System Lung device for bilateral lung transplantation (INSPIRE): a randomised, open-label, non-inferiority, phase 3 study. Lancet Respir Med. 2018;6(5):357–67. study is a non-inferiority, randomised, controlled, open-label, phase 3 trial, targeting double lung transplant recipient of stand criteria donor lungs [OCS (n= 151) vs. Control (n= 169)]. The INSPIRE trial met its primary effectiveness and safety endpoints with no short-term survival benefit. CrossRefGoogle Scholar
  4. 4.
    Fisher A, Andreasson A, Chrysos A, Lally J, Mamasoula C, Exley C, et al. An observational study of donor ex vivo lung perfusion in UK lung transplantation: DEVELOP-UK. Health Technol Assess. 2016;20(85):1–276. Scholar
  5. 5.
    Wallinder A, Riise GC, Ricksten S-E, Silverborn M, Dellgren G. Transplantation after ex vivo lung perfusion: a midterm follow-up. J Heart Lung Transplant. 2016;35(11):1303–10. Scholar
  6. 6.
    Sage E, Mussot S, Trebbia G, Puyo P, Stern M, Dartevelle P, et al. Lung transplantation from initially rejected donors after ex vivo lung reconditioning: the French experience. Eur J Cardiothorac Surg. 2014;46(5):794–9. Scholar
  7. 7.
    •• Slama A, Schillab L, Barta M, Benedek A, Mitterbauer A, Hoetzenecker K, et al. Standard donor lung procurement with normothermic ex vivo lung perfusion: a prospective randomized clinical trial. J Heart Lung Transplant. 2017;36(7):744–53. study is a prospective single-center randomized clinical trialthat compared patients (n= 39) who underwent transplant with EVLP-evaluated donor lungs with controls (n= 41) using standard criteria donor lungs. They conclude that EVLP can safely be used in standard donor lungs and allows clinicians to identify and to possibly exclude lungs with functional impairment. CrossRefGoogle Scholar
  8. 8.
    Kerr J, Baker N, Bassett D, Fisher A. Effect of perfusate glucose concentration on rat lung glycolysis. Am J Physiol Endocrinol Metab. 1979;236(3):E229. Scholar
  9. 9.
    Czartolomna J, Voelkel NF, Chang SW. Permeability characteristics of isolated perfused rat lungs. J Appl Physiol. 1991;70(4):1854–60. Scholar
  10. 10.
    Niemeier R. The isolated perfused lung. Environ Health Perspect. 1984;56:35–41. Scholar
  11. 11.
    Bassani GA, Lonati C, Brambilla D, Rapido F, Valenza F, Gatti S. Ex vivo lung perfusion in the rat: detailed procedure and videos. PLoS One. 2016;11(12):e0167898. Scholar
  12. 12.
    Noda K, Shigemura N, Tanaka Y, Bhama JK, D’Cunha J, Luketich JD, et al. Successful prolonged ex vivo lung perfusion for graft preservation in rats. Eur J Cardiothorac Surg. 2014;45(3):e54–60. Scholar
  13. 13.
    DeCampos KN, Keshavjee S, Slutsky AS, Liu M. Alveolar recruitment prevents rapid-reperfusion-induced injury of lung transplants. J Heart Lung Transplant. 1999;18(11):1096–102. Scholar
  14. 14.
    Fujinaga T, Nakamura T, Fukuse T, Chen F, Zhang J, Ueda S, et al. Isoflurane inhalation after circulatory arrest protects against warm ischemia reperfusion injury of the lungs. Transplantation. 2006;82(9):1168–74. Scholar
  15. 15.
    Inokawa H, Sevala M, Funkhouser WK, Egan TM. Ex-vivo perfusion and ventilation of rat lungs from non-heart-beating donors before transplant. Ann Thorac Surg. 2006;82(4):1219–25. Scholar
  16. 16.
    Fukuse T, Albes JM, Takahashi Y, Brandes H, Hausen B, Schafers HJ. Influence of red blood cells on lung function in an ex vivo rat heart-lung model. J Surg Res. 1995;59(3):399–404. Scholar
  17. 17.
    Dong B, Stewart PW, Egan TM. Postmortem and ex vivo carbon monoxide ventilation reduces injury in rat lungs transplanted from non-heart-beating donors. J Thorac Cardiovasc Surg. 2013;146(2):429–36 e1. Scholar
  18. 18.
    Pierre AF, DeCampos KN, Liu M, Edwards V, Cutz E, Slutsky AS, et al. Rapid reperfusion causes stress failure in ischemic rat lungs. J Thorac Cardiovasc Surg. 1998;116(6):932–42. Scholar
  19. 19.
    Steen S, Liao Q, Wierup PN, Bolys R, Pierre L, Sjöberg T. Transplantation of lungs from non-heart-beating donors after functional assessment ex vivo. Ann Thorac Surg. 2003;76(1):244–52. Scholar
  20. 20.
    Cypel M, Yeung JC, Hirayama S, Rubacha M, Fischer S, Anraku M, et al. Technique for prolonged normothermic ex vivo lung perfusion. J Heart Lung Transplant. 2008;27(12):1319–25. Scholar
  21. 21.
    Cypel M, Rubacha M, Yeung J, Hirayama S, Torbicki K, Madonik M, et al. Normothermic ex vivo perfusion prevents lung injury compared to extended cold preservation for transplantation. Am J Transplant. 2009;9(10):2262–9. Scholar
  22. 22.
    Mulloy DP, Stone ML, Crosby IK, Lapar DJ, Sharma AK, Webb DV, et al. Ex vivo rehabilitation of non-heart-beating donor lungs in preclinical porcine model: delayed perfusion results in superior lung function. J Thorac Cardiovasc Surg. 2012;144(5):1208–15. Scholar
  23. 23.
    U.S. Department of Health and Human Services Food and Drug Administration Center for Devise s and Radiological Health. Utilizing animal studies to evaluate organ preservation devices. Accessed 21 Nov 2019.
  24. 24.
    Steen S, Ingemansson R, Eriksson L, Pierre L, Algotsson L, Wierup P, et al. First human transplantation of a nonacceptable donor lung after reconditioning ex vivo. Ann Thorac Surg. 2007;83(6):2191–4. Scholar
  25. 25.
    Okamoto T, Wheeler D, Liu Q, Quintini C, Hata JS, McCurry KR. Variability in pressure of arterial oxygen to fractional inspired oxygen concentration ratio during cellular ex vivo lung perfusion: implication for decision making. Transplantation. 2015;99(12):2504–13. Scholar
  26. 26.
    Niikawa H, Okamoto T, Ayyat K, Itoda Y, Hata J, McCurry K. A Novel parameter of lung evaluation utilizing PaO2/FiO2 difference at the different FiO2 in ex vivo lung perfusion. J Heart Lung Transplant. 2018;37(4):S148.CrossRefGoogle Scholar
  27. 27.
    Okamoto T, Wheeler D, Liu Q, Quintini C, Hata JS, McCurry KR. Correlation between PaO2/FiO2 and airway and vascular parameters in the assessment of cellular ex vivo lung perfusion system. J Heart Lung Transplant. 2016;35(11):1330–6. Scholar
  28. 28.
    Yeung JC, Cypel M, Machuca TN, Koike T, Cook DJ, Bonato R, et al. Physiologic assessment of the ex vivo donor lung for transplantation. J Heart Lung Transplant. 2012;31(10):1120–6. Scholar
  29. 29.
    Zeriouh M, Sabashnikov A, Mohite PN, Zych B, Patil NP, Garcia-Saez D, et al. Utilization of the organ care system for bilateral lung transplantation: preliminary results of a comparative study. Interact Cardiovasc Thorac Surg. 2016;23(3):351–7. Scholar
  30. 30.
    Steen S, Sjoberg T, Pierre L, Liao Q, Eriksson L, Algotsson L. Transplantation of lungs from a non-heart-beating donor. Lancet. 2001;357(9259):825–9. Scholar
  31. 31.
    Rega FR, Jannis NC, Verleden GM, Flameng WJ, Lerut TE, Van Raemdonck DE. Should we ventilate or cool the pulmonary graft inside the non-heart-beating donor? J Heart Lung Transplant. 2003;22(11):1226–33. Scholar
  32. 32.
    Bennett DT, Reece TB, Smith PD, Grandhi MS, Jessica A, Justison GA, et al. Ex vivo lung perfusion allows successful transplantation of donor lungs from hanging victims. Ann Thorac Surg. 2014;98(3):1051–6. Scholar
  33. 33.
    Niikawa H, Okamoto T, Ayyat KS, Itoda Y, Hata JS, McCurry KR. Significant parameters in the evaluation of donor lungs in single-lung cellular ex vivo lung perfusion. Interact Cardiovasc Thorac Surg. 2018. Scholar
  34. 34.
    Erasmus ME, Fernhout MH, Elstrodt JM, Rakhorst G. Normothermic ex vivo lung perfusion of non-heart-beating donor lungs in pigs: from pretransplant function analysis towards a 6-h machine preservation. Transpl Int. 2006;19(7):589–93. Scholar
  35. 35.
    Ingemansson R, Eyjolfsson A, Mared L, Pierre L, Algotsson L, Ekmehag B, et al. Clinical transplantation of initially rejected donor lungs after reconditioning ex vivo. Ann Thorac Surg. 2009;87(1):255–60. Scholar
  36. 36.
    Wallinder A, Ricksten SE, Hansson C, Riise GC, Silverborn M, Liden H, et al. Transplantation of initially rejected donor lungs after ex vivo lung perfusion. J Thorac Cardiovasc Surg. 2012;144(5):1222–8. Scholar
  37. 37.
    Cypel M, Yeung JC, Machuca T, Chen M, Singer LG, Yasufuku K, et al. Experience with the first 50 ex vivo lung perfusions in clinical transplantation. J Thorac Cardiovasc Surg. 2012;144(5):1200–6. Scholar
  38. 38.
    Warnecke G, Moradiellos J, Tudorache I, Kuhn C, Avsar M, Wiegmann B, et al. Normothermic perfusion of donor lungs for preservation and assessment with the Organ Care System Lung before bilateral transplantation: a pilot study of 12 patients. Lancet. 2012;380(9856):1851–8. Scholar
  39. 39.
    •• Yeung JC, Krueger T, Yasufuku K, de Perrot M, Pierre AF, Waddell TK, et al. Outcomes after transplantation of lungs preserved for more than 12 h: a retrospective study. Lancet Respir Med. 2017;5(2):119–24. study is the first publication retrospectively showing acceptable preservation time of perfused lungs in large volume cases. CrossRefPubMedGoogle Scholar
  40. 40.
    Hsin MK, Iskender I, Nakajima D, Chen M, Kim H, Dos Santos PR, et al. Extension of donor lung preservation with hypothermic storage after normothermic ex vivo lung perfusion. J Heart Lung Transplant. 2016;35(1):130–6. Scholar
  41. 41.
    Cypel M, Yeung JC, Keshavjee S. Introducing the concept of semi-elective lung transplantation using ex vivo lung perfusion. Elsevier; 2018.Google Scholar
  42. 42.
    Loor G, Howard BT, Spratt JR, Mattison LM, Panoskaltsis-Mortari A, Brown RZ, et al. Prolonged EVLP using OCS lung: cellular and acellular perfusates. Transplantation. 2017;101(10):2303–11. Scholar
  43. 43.
    Takahashi M, Cheung H, Chen M, Watanabe Y, Watanabe T, Harmantas C, et al. Twenty-four hour ex vivo lung perfusion: strategies to stabilize extended EVLP in a pig model. J Heart Lung Transplant. 2018;37(4):S223.CrossRefGoogle Scholar
  44. 44.
    • Sommer W, Salman J, Avsar M, Hoeffler K, Jansson K, Siemeni TN, et al. Prediction of transplant outcome after 24-hour ex vivo lung perfusion using the Organ Care System in a porcine lung transplantation model. Am J Transplant. 2019;19(2):345–55. study is the first report of successful 24 h of prolonged perfusion of porcine lungs in OCS, suggesting that STEEN solution plus red blood cells is favorable compared with other perfusates (STEEN solution only or STEEN solution plus low potassium dextran). CrossRefGoogle Scholar
  45. 45.
    Cypel M, Liu M, Rubacha M, Yeung JC, Hirayama S, Anraku M, et al. Functional repair of human donor lungs by IL-10 gene therapy. Sci Transl Med. 2009;1(4):4ra9. Scholar
  46. 46.
    Andreasson A, Karamanou DM, Perry JD, Perry A, Ӧzalp F, Butt T, et al. The effect of ex vivo lung perfusion on microbial load in human donor lungs. J Heart Lung Transplant. 2014;33(9):910–6. Scholar
  47. 47.
    Nakajima D, Cypel M, Bonato R, Machuca TN, Iskender I, Hashimoto K, et al. Ex vivo perfusion treatment of infection in human donor lungs. Am J Transplant. 2016. Scholar
  48. 48.
    •• Galasso M, Feld JJ, Watanabe Y, Pipkin M, Summers C, Ali A, et al. Inactivating hepatitis C virus in donor lungs using light therapies during normothermic ex vivo lung perfusion. Nat Commun. 2019;10, 481 This study provides a novel technology of physical viral clearance using germicidal light-based therapy during EVLP. Google Scholar
  49. 49.
    Roman M, Gjorgjimajkoska O, Neil D, Nair S, Colah S, Parmar J, et al. Comparison between cellular and acellular perfusates for ex vivo lung perfusion in a porcine model. J Heart Lung Transplant. 2015;34(7):978–87. Scholar
  50. 50.
    Becker S, Steinmeyer J, Avsar M, Höffler K, Salman J, Haverich A, et al. Evaluating acellular versus cellular perfusate composition during prolonged ex vivo lung perfusion after initial cold ischaemia for 24 hours. Transpl Int. 2016;29(1):88–97.CrossRefGoogle Scholar
  51. 51.
    Steinmeyer J, Becker S, Avsar M, Salman J, Höffler K, Haverich A, et al. Cellular and acellular ex vivo lung perfusion preserve functional lung ultrastructure in a large animal model: a stereological study. Respir Res. 2018;19(1):238.Google Scholar
  52. 52.
    • Nilsson T, Gielis JF, Slama A, Hasson C, Wallinder A, Ricksten SE, et al. Comparison of two strategies for ex vivo lung perfusion. J Heart Lung Transplant. 2018;37(2):292–8. study describes a comparison of two EVLP protocols using porcine lungs, and suggested the trend that lung edema and decreased lung compliance were more pronounced in acellular closed left atrium group compared with cellular open left atrium group. CrossRefGoogle Scholar
  53. 53.
    • Okamoto T. Wheeler D. Farver CF; McCurry KR. Transplant suitability of rejected human donor lungs with prolonged cold ischemia time in low flow acellular and high flow cellular ex vivo lung perfusion systems. Transplantation: 2019; 103(9): 1799-1808 This study demonstrates that the potential for reconditioning rejected human lungs with CIT greater than 8 hours (mean 13.8 hours) is limited due to severe ischemia reperfusion injury in two EVLP protocols.CrossRefGoogle Scholar
  54. 54.
    Peták F, Habre W, Hantos Z, Sly PD, Morel DR. Effects of pulmonary vascular pressures and flow on airway and parenchymal mechanics in isolated rat lungs. J Appl Physiol. 2002;92(1):169–78. Scholar
  55. 55.
    Linacre V, Cypel M, Machuca T, Nakajima D, Hashimoto K, Zamel R, et al. Importance of left atrial pressure during ex vivo lung perfusion. J Heart Lung Transplant. 2016;35(6):808–14. Scholar
  56. 56.
    Slutsky AS, Ranieri VM. Ventilator-induced lung injury. N Engl J Med. 2013;369(22):2126–36. Scholar
  57. 57.
    Terragni PP, Fanelli V, Boffini M, Filippini C, Cappello P, Ricci D, et al. Ventilatory management during normothermic ex vivo lung perfusion: effects on clinical outcomes. Transplantation. 2016;100(5):1128–35. Scholar
  58. 58.
    • Mehaffey JH, Charles EJ, Sharma AK, Salmon M, Money D, Schubert S, et al. Airway pressure release ventilation during ex vivo lung perfusion attenuates injury. J Thorac Cardiovasc Surg. 2017;153(1):197–204. study provide an evidence that airway pressure release ventilation during EVLP might be protective, compared with the current standard lung protective ventilation setting. CrossRefGoogle Scholar
  59. 59.
    Aboelnazar NS, Himmat S, Hatami S, White CW, Burhani MS, Dromparis P, et al. Negative pressure ventilation decreases inflammation and lung edema during normothermic ex-vivo lung perfusion. J Heart Lung Transplant. 2018;37(4):520–30. Scholar
  60. 60.
    Noda K, Tane S, Haam SJ, Hayanga AJ, D’Cunha J, Luketich JD, et al. Optimal ex vivo lung perfusion techniques with oxygenated perfusate. J Heart Lung Transplant. 2017;36(4):466–74. Scholar
  61. 61.
    Luc JG, Aboelnazar NS, Himmat S, Hatami S, Haromy A, Matsumura N, et al. A leukocyte filter does not provide further benefit during ex vivo lung perfusion. ASAIO J. 2017;63(5):672–8. Scholar
  62. 62.
    Noda K, Tane S, Haam SJ, D’cunha J, Hayanga AJ, Luketich JD, et al. Targeting circulating leukocytes and pyroptosis during ex vivo lung perfusion improves lung preservation. Transplantation. 2017;101(12):2841–9. Scholar
  63. 63.
    Schumer EM, Zoeller KA, Linsky PL, Monreal G, Choi Y, Giridharan GA, et al. Feasibility study of pulsatile left ventricular assist device for prolonged ex vivo lung perfusion. Ann Thorac Surg. 2015;99(6):1961–8. Scholar
  64. 64.
    Bloomfield R, Noble DW, Sudlow A. Prone position for acute respiratory failure in adults. Cochrane Database Syst Rev. 2015;11:CD008095. Scholar
  65. 65.
    • Niikawa H, Okamoto T, Ayyat KS, Itoda Y, Farver CF, McCurry KR. The protective effect of prone lung position on ischemia-reperfusion injury and lung function in an ex vivo porcine lung model. J Thorac Cardiovasc Surg. 2019;157(1):425–33. study demonstrate that prone position of porcine lungs in EVLP was associated with better oxygenation and lower lung weight ratio and lower IL-1 beta level, compared with the supine positioned lungs. CrossRefGoogle Scholar
  66. 66.
    Costa J, Sreekanth S, Kossar A, Raza K, Lederer DJ, Robbins H, et al. Donor lung assessment using selective pulmonary vein gases. Eur J Cardiothorac Surg. 2016;50(5):826–31. Scholar
  67. 67.
    Venkateswaran RV, Dronavalli V, Patchell V, Wilson I, Mascaro J, Thompson R, et al. Measurement of extravascular lung water following human brain death: implications for lung donor assessment and transplantation. Eur J Cardiothorac Surg. 2012;43(6):1227–32.CrossRefGoogle Scholar
  68. 68.
    Trebbia G, Sage E, Le Guen M, Roux A, Soummer A, Puyo P, et al. Assessment of lung edema during ex-vivo lung perfusion by single transpulmonary thermodilution: A preliminary study in humans. J Heart Lung Transplant. 2018. Scholar
  69. 69.
    Ayyat K, Okamoto T, Niikawa H, Itoda Y, Dugar S Q, Latifi S, et al. DireCt lung ultrasound evaluation (CLUE): a novel technique for monitoring extravascular lung water in donor lungs. J Heart Lung Transplant. 2019; 38(7): 757-66.CrossRefGoogle Scholar
  70. 70.
    Molina DK, DiMaio VJ. Normal organ weights in men: part II—the brain, lungs, liver, spleen, and kidneys. Am J Forensic Med Pathol. 2012;33(4):368–72. Scholar
  71. 71.
    Molina DK, DiMaio VJ. Normal organ weights in women: part II—the brain, lungs, liver, spleen, and kidneys. Am J Forensic Med Pathol. 2015;36(3):182–7. Scholar
  72. 72.
    Tagami T, Kushimoto S, Yamamoto Y, Atsumi T, Tosa R, Matsuda K, et al. Validation of extravascular lung water measurement by single transpulmonary thermodilution: human autopsy study. Crit Care. 2010;14(5):R162.CrossRefPubMedGoogle Scholar
  73. 73.
    Andreasson AS, Borthwick LA, Gillespie C, Jiwa K, Scott J, Henderson P, et al. The role of interleukin-1β as a predictive biomarker and potential therapeutic target during clinical ex vivo lung perfusion. J Heart Lung Transplant. 2017;36(9):985–95. Scholar
  74. 74.
    Machuca TN, Cypel M, Yeung JC, Bonato R, Zamel R, Chen M, et al. Protein expression profiling predicts graft performance in clinical ex vivo lung perfusion. Ann Surg. 2015;261(3):591–7. Scholar
  75. 75.
    Hsin MK, Zamel R, Cypel M, Wishart D, Han B, Keshavjee S, et al. Metabolic profile of ex vivo lung perfusate yields biomarkers for lung transplant outcomes. Ann Surg. 2018;267(1):196–7. Scholar
  76. 76.
    Wallinder A, Hansson C, Dellgren G. Hemoconcentration in ex vivo lung perfusion: a case report of a novel technique used in clinical lung transplantation. J Thorac Cardiovasc Surg. 2013;145(6):e76–7. Scholar
  77. 77.
    Nilsson T, Hansson C, Wallinder A, Malm CJ, Silverborn M, Ricksten SE, et al. Hemofiltration in ex vivo lung perfusion-a study in experimentally induced pulmonary edema. J Thorac Cardiovasc Surg. 2016;151(2):570–5 e1. Scholar
  78. 78.
    Khalifé-Hocquemiller T, Sage E, Dorfmuller P, Mussot S, Le Houérou D, Eddahibi S, et al. Exogenous surfactant attenuates lung injury from gastric-acid aspiration during ex vivo reconditioning in pigs. Transplantation. 2014;97(4):413–8. Scholar
  79. 79.
    Inci I, Hillinger S, Arni S, Kaplan T, Inci D, Weder W. Reconditioning of an injured lung graft with intrabronchial surfactant instillation in an ex vivo lung perfusion system followed by transplantation. J Surg Res. 2013;184(2):1143–9. Scholar
  80. 80.
    Nakajima D, Liu M, Ohsumi A, Kalaf R, Iskender I, Hsin M, et al. Lung lavage and surfactant replacement during ex vivo lung perfusion for treatment of gastric acid aspiration–induced donor lung injury. J Heart Lung Transplant. 2017;36(5):577–85. Scholar
  81. 81.
    Huang C-S, Kawamura T, Toyoda Y, Nakao A. Recent advances in hydrogen research as a therapeutic medical gas. Free Radic Res. 2010;44(9):971–82. Scholar
  82. 82.
    Noda K, Shigemura N, Tanaka Y, Bhama J, D’cunha J, Kobayashi H, et al. Hydrogen preconditioning during ex vivo lung perfusion improves the quality of lung grafts in rats. Transplantation. 2014;98(5):499–506.CrossRefGoogle Scholar
  83. 83.
    Haam S, Lee S, Paik HC, Park MS, Song JH, Lim BJ, et al. The effects of hydrogen gas inhalation during ex vivo lung perfusion on donor lungs obtained after cardiac death. Eur J Cardiothorac Surg. 2015;48(4):542–7. Scholar
  84. 84.
    Ware LB, Fang X, Wang Y, Babcock WD, Jones K, Matthay MA. High prevalence of pulmonary arterial thrombi in donor lungs rejected for transplantation. J Heart Lung Transplant. 2005;24(10):1650–6. Scholar
  85. 85.
    Oto T, Rabinov M, Griffiths AP, Whitford H, Levvey BJ, Esmore DS, et al. Unexpected donor pulmonary embolism affects early outcomes after lung transplantation: a major mechanism of primary graft failure? J Thorac Cardiovasc Surg. 2005;130(5):1446. e1-9. Scholar
  86. 86.
    Brown CR, Brozzi NA, Vakil N, Shafii AE, Murthy SC, Pettersson GB, et al. Donor lungs with pulmonary embolism evaluated with ex vivo lung perfusion. ASAIO J. 2012;58(4):432–4. Scholar
  87. 87.
    Inci I, Zhai W, Arni S, Inci D, Hillinger S, Lardinois D, et al. Fibrinolytic treatment improves the quality of lungs retrieved from non-heart-beating donors. J Heart Lung Transplant. 2007;26(10):1054–60. Scholar
  88. 88.
    Inci I, Yamada Y, Hillinger S, Jungraithmayr W, Trinkwitz M, Weder W. Successful lung transplantation after donor lung reconditioning with urokinase in ex vivo lung perfusion system. Ann Thorac Surg. 2014;98(5):1837–8. Scholar
  89. 89.
    Motoyama H, Chen F, Hijiya K, Kondo T, Ohsumi A, Yamada T, et al. Plasmin administration during ex vivo lung perfusion ameliorates lung ischemia–reperfusion injury. J Heart Lung Transplant. 2014;33(10):1093–9. Scholar
  90. 90.
    Machuca TN, Hsin MK, Ott HC, Chen M, Hwang DM, Cypel M, et al. Injury-specific ex vivo treatment of the donor lung: pulmonary thrombolysis followed by successful lung transplantation. Am J Respir Crit Care Med. 2013;188(7):878–80. Scholar
  91. 91.
    Harada M, Oto T, Otani S, Miyoshi K, Okada M, Iga N, et al. A neutrophil elastase inhibitor improves lung function during ex vivo lung perfusion. Gen Thorac Cardiovasc Surg. 2015;63(12):645–51.CrossRefGoogle Scholar
  92. 92.
    Lin H, Chen M, Tian F, Tikkanen J, Ding L, Andrew Cheung HY, et al. α1-Anti-trypsin improves function of porcine donor lungs during ex-vivo lung perfusion. J Heart Lung Transplant. 2018;37(5):656–66. Scholar
  93. 93.
    Charles EJ, Mehaffey JH, Sharma AK, Zhao Y, Stoler MH, Isbell JM, et al. Lungs donated after circulatory death and prolonged warm ischemia are transplanted successfully after enhanced ex vivo lung perfusion using adenosine A2B receptor antagonism. J Thorac Cardiovasc Surg. 2017;154(5):1811–20. Scholar
  94. 94.
    Okamoto T, Niikawa H, Wheeler D, Ayyat K, Soliman B, Itoda Y, et al. Selective recruitment of large lower lobe atelectasis on donor back table in rejected donor lungs. Transpl Direct. 2019;5(5):e453 In Press.CrossRefGoogle Scholar
  95. 95.
    Fukuse T, Hirata T, Nakamura T, Kawashima M, Hitomi S, Wada H. Influence of deflated and anaerobic conditions during cold storage on rat lungs. Am J Respir Crit Care Med. 1999;160(2):621–7. Scholar
  96. 96.
    •• Levvey B, Keshavjee S, Cypel M, Robinson A, Erasmus M, Glanville A, et al. Influence of lung donor agonal and warm ischemic times on early mortality: analyses from the ISHLT DCD Lung Transplant Registry. J Heart Lung Transplant. 2019;38(1):26–34. study is the largest retrospective study (n= 507) of outcomes of category III DCD donors using ISHLT DCD Lung Transplant Registry. They conclude that day 30 and 1-year survival were not statistically different according to agonal or warm ischemic time category. CrossRefGoogle Scholar
  97. 97.
    Machuca T, Mercier O, Collaud S, Tikkanen J, Krueger T, Yeung J, et al. Lung transplantation with donation after circulatory determination of death donors and the impact of ex vivo lung perfusion. Am J Transplant. 2015;15(4):993–1002. Scholar
  98. 98.
    Mason DP, Brown CR, Murthy SC, Vakil N, Lyon C, Budev MM, et al. Growing single-center experience with lung transplantation using donation after cardiac death. Ann Thorac Surg. 2012;94(2):406–12. Scholar
  99. 99.
    • Costa J, Shah L, Robbins H, Raza K, Sreekandth S, Arcasoy S, et al. Use of lung allografts from donation after cardiac death donors: a single-center experience. Ann Thorac Surg. 2018;105(1):271–8. study is a recent single-center retrospective study (n= 73) of category III DCD donor lungs on 2007–2016. Recipients from DCD donors (n= 46, dry run rate: 40%) shows equivalent PGD rate at 72 h and 1- and 3-year survival compared with controls. CrossRefGoogle Scholar
  100. 100.
    Levvey B, Harkess M, Hopkins P, Chambers D, Merry C, Glanville A, et al. Excellent clinical outcomes from a national donation-after-determination-of-cardiac-death lung transplant collaborative. Am J Transplant. 2012;12(9):2406–13. Scholar
  101. 101.
    Gámez P, Córdoba M, Ussetti P, Carreño MAC, Alfageme F, Madrigal L, et al. Lung transplantation from out-of-hospital non-heart-beating lung donors. one-year experience and results. J Heart Lung Transplant. 2005;24(8):1098–102. Scholar
  102. 102.
    Suzuki Y, Tiwari J, Lee J, Diamond J, Blumenthal N, Carney K, et al. Should we reconsider lung transplantation through uncontrolled donation after circulatory death? Am J Transplant. 2014;14(4):966–71. Scholar
  103. 103.
    Egan T, Requard J III. Uncontrolled donation after circulatory determination of death donors (uDCDDs) as a source of lungs for transplant. Am J Transplant. 2015;15(8):2031–6. Scholar
  104. 104.
    Valenza F, Citerio G, Palleschi A, Vargiolu A, Fakhr BS, Confalonieri A, et al. Successful transplantation of lungs from an uncontrolled donor after circulatory death preserved in situ by alveolar recruitment maneuvers and assessed by ex vivo lung perfusion. Am J Transplant. 2016;16(4):1312–8. Scholar
  105. 105.
    Lindstedt S, Hlebowicz J, Koul B, Wierup P, Sjögren J, Gustafsson R, et al. Comparative outcome of double lung transplantation using conventional donor lungs and non-acceptable donor lungs reconditioned ex vivo. Interact Cardiovasc Thorac Surg. 2011;12(2):162–5. Scholar
  106. 106.
    Alessandrini F, D’Armini AM, Roberts CS, Reddick RL, Egan TM. When does the lung die? II. Ultrastructural evidence of pulmonary viability after “death”. J Heart Lung Transplant. 1994;13(5):748–57.Google Scholar
  107. 107.
    Zych B, Popov AF, Stavri G, Bashford A, Bahrami T, Amrani M, et al. Early outcomes of bilateral sequential single lung transplantation after ex-vivo lung evaluation and reconditioning. J Heart Lung Transplant. 2012;31(3):274–81. Scholar
  108. 108.
    Aigner C, Slama A, Hötzenecker K, Scheed A, Urbanek B, Schmid W, et al. Clinical ex vivo lung perfusion—pushing the limits. Am J Transplant. 2012;12(7):1839–47. Scholar
  109. 109.
    Valenza F, Rosso L, Coppola S, Froio S, Palleschi A, Tosi D, et al. Ex vivo lung perfusion to improve donor lung function and increase the number of organs available for transplantation. Transpl Int. 2014;27(6):553–61. Scholar
  110. 110.
    Henriksen I, Møller-Sørensen H, Møller CH, Zemtsovski M, Nilsson JC, Seidelin CT, et al. First Danish experience with ex vivo lung perfusion of donor lungs before transplantation. Danish Med J. 2014;61(3):A4809.Google Scholar
  111. 111.
    Zhang ZL, van Suylen V, van Zanden JE, Van De Wauwer C, Verschuuren EA, van der Bij W, et al. First experience with ex vivo lung perfusion for initially discarded donor lungs in the Netherlands: a single-centre study. Eur J Cardiothorac Surg. 2018;55(5):920–6. Scholar
  112. 112.
    Schiavon M, Faggi G, Rebusso A, Lunardi F, Comacchio G, Di Gregorio G, et al. Extended criteria donor lung reconditioning with the organ care system lung: a single institution experience. Transpl Int. 2019;32(2):131–40. Scholar
  113. 113.
    Koch A, Pizanis N, Olbertz C, Abou-Issa O, Taube C, Slama A, et al. One-year experience with ex vivo lung perfusion: preliminary results from a single center. Int J Artif Organs. 2018;41(8):460–6. Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Toshihiro Okamoto
    • 1
    • 2
    • 3
    Email author
  • Hiromichi Niikawa
    • 1
    • 2
  • Kamal Ayyat
    • 1
    • 2
  • Ichiro Sakanoue
    • 1
    • 2
  • Sayf Said
    • 2
  • Kenneth R. McCurry
    • 1
    • 2
    • 3
    Email author
  1. 1.Department of Thoracic and Cardiovascular SurgeryClevelandUSA
  2. 2.Department of Inflammation & ImmunityLerner Research InstituteClevelandUSA
  3. 3.Transplant CenterCleveland ClinicClevelandUSA

Personalised recommendations